Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES The global burden of non-alcoholic fatty liver disease (NAFLD) is rising. An alternative term, metabolic dysfunction-associated fatty liver disease (MAFLD), instead highlights the associated metabolic risks. This cohort study examined patient classifications under NAFLD and MAFLD criteria and their associations with all-cause mortality. METHODS Participants who attended a paid health check-up (2012-2015) were included. Hepatic steatosis (HS) was diagnosed ultrasonographically. NAFLD was defined as HS without secondary causes, while MAFLD involved HS with overweight/obesity, type 2 diabetes mellitus, or ≥2 metabolic dysfunctions. Mortality was tracked via the Taiwan Death Registry until November 30, 2022. RESULTS Of 118,915 participants, 36.9% had NAFLD, 40.2% had MAFLD, and 32.9% met both definitions. Participants with NAFLD alone had lower mortality, and those with MAFLD alone had higher mortality, than individuals with both conditions. After adjustment for potential confounders, the hazard ratios (HRs) for all-cause mortality were 1.08 (95% confidence interval [CI], 0.78 to 1.48) for NAFLD alone and 1.26 (95% CI, 1.09 to 1.47) for MAFLD alone, relative to both conditions. Advanced fibrosis conferred greater mortality risk, with HRs of 1.93 (95% CI, 1.44 to 2.58) and 2.08 (95% CI, 1.61 to 2.70) for advanced fibrotic NAFLD and MAFLD, respectively. Key mortality risk factors for NAFLD and MAFLD included older age, unmarried status, higher body mass index, smoking, diabetes mellitus, chronic kidney disease, and advanced fibrosis. CONCLUSIONS All-cause mortality in NAFLD and/or MAFLD was linked to cardiometabolic covariates, with risk attenuated after multivariable adjustment. A high fibrosis-4 index score, indicating fibrosis, could identify fatty liver disease cases involving elevated mortality risk.
Abstract
OBJECTIVES The global burden of non-alcoholic fatty liver disease (NAFLD) is rising. An alternative term, metabolic dysfunction-associated fatty liver disease (MAFLD), instead highlights the associated metabolic risks. This cohort study examined patient classifications under NAFLD and MAFLD criteria and their associations with all-cause mortality. METHODS Participants who attended a paid health check-up (2012-2015) were included. Hepatic steatosis (HS) was diagnosed ultrasonographically. NAFLD was defined as HS without secondary causes, while MAFLD involved HS with overweight/obesity, type 2 diabetes mellitus, or ≥2 metabolic dysfunctions. Mortality was tracked via the Taiwan Death Registry until November 30, 2022. RESULTS Of 118,915 participants, 36.9% had NAFLD, 40.2% had MAFLD, and 32.9% met both definitions. Participants with NAFLD alone had lower mortality, and those with MAFLD alone had higher mortality, than individuals with both conditions. After adjustment for potential confounders, the hazard ratios (HRs) for all-cause mortality were 1.08 (95% confidence interval [CI], 0.78 to 1.48) for NAFLD alone and 1.26 (95% CI, 1.09 to 1.47) for MAFLD alone, relative to both conditions. Advanced fibrosis conferred greater mortality risk, with HRs of 1.93 (95% CI, 1.44 to 2.58) and 2.08 (95% CI, 1.61 to 2.70) for advanced fibrotic NAFLD and MAFLD, respectively. Key mortality risk factors for NAFLD and MAFLD included older age, unmarried status, higher body mass index, smoking, diabetes mellitus, chronic kidney disease, and advanced fibrosis. CONCLUSIONS All-cause mortality in NAFLD and/or MAFLD was linked to cardiometabolic covariates, with risk attenuated after multivariable adjustment. A high fibrosis-4 index score, indicating fibrosis, could identify fatty liver disease cases involving elevated mortality risk.
참고문헌 (32)
- Saklayen MG, "The global epidemic of the metabolic syndrome", Curr Hypertens Rep, 20, pp.12~ (2018)[DOI]
- Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)[DOI]
- Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)[DOI]
- Nassir F, "NAFLD : mechanisms, treatments, and biomarkers", Biomolecules, 12, pp.824~ (2022)[DOI]
- Lazarus JV, "Advancing the global public health agenda for NAFLD : a consensus statement", Nat Rev Gastroenterol Hepatol, 19, pp.60~78 (2022)[DOI]
- Wong VW, "Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-part 1 : definition, risk factors and assessment", J Gastroenterol Hepatol, 33, pp.70~85 (2018)[DOI]
- Guo Y, "Metabolic dysfunction-associated fatty liver disease is associated with the risk of incident cardiovascular disease : a prospective cohort study in Xinjiang", Nutrients, 14, pp.2361~ (2022)[DOI]
- Nguyen VH, "Differential clinical characteristics and mortality outcomes in persons with NAFLD and", or MAFLD, 2021, pp.19, 2172~2181
- Lee H, "Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk : a nationwide cohort study", Clin Gastroenterol Hepatol, 19, pp.2138~2147 (2021)[DOI]
- Wu X, "Cohort profile : the Taiwan MJ Cohort : half a million Chinese with repeated health surveillance data", Int J Epidemiol, 46, pp.1744~ (2017)[DOI]
- Wen CP, "Minimum amount of physical activity for reduced mortality and extended life expectancy : a prospective cohort study", Lancet, 378, pp.1244~1253 (2011)[DOI]
- Martinez-Gomez D, "Physical activity and risk of metabolic phenotypes of obesity : a prospective Taiwanese cohort study in more than 200, 000 adults", Mayo Clin Proc, 94, pp.2209~2219 (2019)[DOI]
- Tsai YL, "Joint effect of changes in physical activity and weight on incident non-alcoholic fatty liver disease", J Epidemiol Community Health, 75, pp.1215~1221 (2021)[DOI]
- Wen CP, "All-cause mortality attributable to chronic kidney disease : a prospective cohort study based on 462 293 adults in Taiwan", Lancet, 371, pp.2173~2182 (2008)[DOI]
- Chen SC, "Liver fat, hepatic enzymes, alkaline phosphatase and the risk of incident type 2 diabetes : a prospective study of 132, 377 adults", Sci Rep, 7, pp.4649~ (2017)[DOI]
- European Association for the Study of the Liver(EASL), "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)[DOI]
- Levey AS, "Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values", Clin Chem, 53, pp.766~772 (2007)[DOI]
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- Kotronen A, "Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors", Gastroenterology, 137, pp.865~872 (2009)[DOI]
- Lee H, "Metabolic dysfunction-associated fatty liver disease increases colon cancer risk : a nationwide cohort study", Clin Transl Gastroenterol, 13, pp.e00435~ (2022)[DOI]
- Allen AM, "Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death : a 20 year-community study", Hepatology, 67, pp.1726~1736 (2018)[DOI]
- Suh Y, "Impact of national health checkup service on hard atherosclerotic cardiovascular disease events and all-cause mortality in the general population", Am J Cardiol, 120, pp.1804~1812 (2017)[DOI]
- Beauchamp A, "Health literacy interventions for secondary prevention of coronary artery disease : a scoping review", Open Heart, 9, pp.e001895~ (2022)[DOI]
- Osborn CY, "The mechanisms linking health literacy to behavior and health status", Am J Health Behav, 35, pp.118~128 (2011)[DOI]
- Younossi ZM, "Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?", Hepatology, 76, pp.1423~1437 (2022)[DOI]
- Allen AM, "Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design", J Hepatol, 77, pp.1237~1245 (2022)[DOI]
- Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)[DOI]
- Szklo M, "Epidemiology: beyond the basics", pp.201~202 (2019), Jones & Bartlett Learning
- Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)[DOI]
- Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)[DOI]
- Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625 (2020)[DOI]
- Shah AG, "Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 7, pp.1104~1112 (2009)[DOI]